Where Revance Therapeutics Stands With Analysts
Portfolio Pulse from Benzinga Insights
Over the past 3 months, 4 analysts have published their opinion on Revance Therapeutics (NASDAQ:RVNC) stock. The company has an average price target of $35.5, a decrease of 5.96% from the previous average price target of $37.75. The majority of the ratings are bullish.
August 09, 2023 | 1:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Revance Therapeutics has received mostly bullish ratings from analysts, with a decreased average price target of $35.5.
The majority of analysts are bullish on Revance Therapeutics, indicating a positive sentiment towards the stock. However, the decrease in the average price target could suggest a potential slowdown in the stock's growth, which might impact its short-term performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100